Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Miralpeix, M. Gómez-Angelats, M. Aparici, M. Viñals, J. Beleta, A. Gavaldà, C. Puig, H. Ryder, J. Llenas, J. Gras (Barcelona, Spain). LAS100977, a novel β₂-agonist, has a longer duration of action and a more favourable therapeutic index than salmeterol in anaesthetised dogs. Eur Respir J 2010; 36: Suppl. 54, 1230

Member's Comments

No comment yet.

Related content which might interest you: Compound X – an inhaled β2 agonist with equivalent potency and superior duration of action (DOA)/ therapeutic index (TI) to salmeterol in the anaesthetised dog model of bronchoconstriction Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 The inhaled anticholinergic agent, aclidinium bromide, reverses cholinergic-induced bronchoconstriction in guinea pigs with a fast onset of action and a long duration of effect Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008 Indacaterol, a novel 24-hour β2-agonist, demonstrates a long duration of action and fast onset in vitro and in vivo in the guinea pig Source: Eur Respir J 2005; 26: Suppl. 49, 122s Year: 2005 Duration and onset of action of indacaterol, a novel 24-hour β2-agonist, on isolated human bronchus Source: Eur Respir J 2005; 26: Suppl. 49, 216s Year: 2005 The bronchodilator effects of the novel anti-inflammatory compound TPI 1020, alone and in combination with formoterol, in conscious guinea pigs Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009 In vivo, aclidinium bromide has longer duration of action and reduced potential to induce dry mouth, compared with glycopyrrolate Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010 AWD 12-281, a new selective PDE4-inhibitor with a high safety margin: separation of anti-inflammatory and emetic effects in ferrets and domestic pigs Source: Eur Respir J 2002; 20: Suppl. 38, 617s Year: 2002 PF-00610355 – an inhaled β2 adrenoceptor agonist with superior potency and duration of action (DoA) to salmeterol in the conscious dog model of bronchoconstriction Source: Annual Congress 2009 - Models of chronic airways disease and therapy Year: 2009 AZD3199: A fast acting β2-receptor agonist with a long duration of action Source: Annual Congress 2011 - Translational models of disease Year: 2011 LAS100977 is a novel, potent β2-agonist with rapid onset and sustained duration of action in vitro Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010 The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 240s Year: 2002 Effects of long acting β2-agonist, sustained-release theophylline and their combination on exercise parameters in asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 287s Year: 2002 Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with asthma Source: Eur Respir J 2007; 30: Suppl. 51, 350s Year: 2007 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol Source: Annual Congress 2008 - New treatments for asthma Year: 2008 Aclidinium bromide, a novel long-acting anticholinergic, does not affect QT interval in healthy subjects Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008 Low systemic exposure of NVA237, an inhaled once-daily anticholinergic bronchodilator, in healthy humans Source: Eur Respir J 2006; 28: Suppl. 50, 661s Year: 2006 Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011 Safety and tolerability of the novel very long acting β2-agonist Carmoterol given as a 2μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006 Indacaterol, a novel 24-hour β2-agonist, is effective and well tolerated on multiple dosing in patients with mild to moderate COPD Source: Eur Respir J 2005; 26: Suppl. 49, 287s Year: 2005 QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013